Advertisement

International Journal of Clinical Oncology

, Volume 12, Issue 2, pp 99–110 | Cite as

Combination of radiotherapy with EGFR antagonists for head and neck carcinoma

  • Juliette Thariat
  • Gokcen Yildirim
  • Kathryn A. Mason
  • Adam S. Garden
  • Luka Milas
  • K. Kian AngEmail author
REVIEW ARTICLE

Abstract

The introduction of biologically sound radiation fractionation regimens and combinations of radiotherapy with chemotherapy have gradually improved both the survival of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and the prospect of organ preservation. Long-term follow-up, however, has shown that some of the radiation–chemotherapy combinations are associated with increased late toxicity. This observation, in conjunction with advances in tumor biology, has led to the launch of investigations into molecular markers and targets for therapeutic interventions. Research on the epidermal growth factor receptor (EGFR)-mediated signaling pathway has enriched our understanding of the biology of HNSCC, in terms of carcinogenesis and cellular processes governing tumor response to therapy. The finding that the addition of an antibody-based inhibitor of the EGFR pathway to radiotherapy significantly improves locoregional control and overall survival rates in patients with locally advanced HNSCC, without increasing radiation-induced toxicity, has resulted in the growing acceptance of such combined regimens as a frontline therapy option for locally advanced HNSCC. Because such therapy has benefited only an additional 10%-15% of patients, studies are being undertaken to identify markers and mechanisms of resistance to EGFR antagonists that are essential for the further refinement of therapy. Overall, preclinical and clinical studies on EGFR have validated the concept that selective tumor radiation sensitization can be achieved by modulating a specific perturbed signaling pathway, and these studies have increased the enthusiasm for developing and investigating other novel agents targeting other cellular processes.

Key words

Radiotherapy Targeted therapy Epidermal growth factor receptor (EGFR) Predictive molecular markers Resistance Angiogenesis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal, A, Siegel, R, Ward, E,  et al. 2006Cancer statistics, 2006CA Cancer J Clin56106130PubMedGoogle Scholar
  2. 2.
    Robert, F, Ezekiel, MP, Spencer, SA,  et al. 2001Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerJ Clin Oncol1932343243PubMedGoogle Scholar
  3. 3.
    Schneider, DO, Whitmore, GF 1963Comparative effects of neutrons and X-rays on mammalian cellsRadiat Res18286306PubMedCrossRefGoogle Scholar
  4. 4.
    Kim, JJ, Tannock, IF 2005Repopulation of cancer cells during therapy: an important cause of treatment failureNat Rev Cancer5516525PubMedCrossRefGoogle Scholar
  5. 5.
    Bourhis, J, Overgaard, J, Audry, H,  et al. 2006Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysisLancet368843854PubMedCrossRefGoogle Scholar
  6. 6.
    Bourhis, J, Armand, C, Pignon, JP 2004Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapyJ Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition)225505Google Scholar
  7. 7.
    Al-Sarraf, M, Pajak, TF, Cooper, JS,  et al. 1990Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group studyJ Clin Oncol813421351PubMedGoogle Scholar
  8. 8.
    Cohen, S 1965The stimulation of epidermal proliferation by a specific protein (EGF)Dev Biol12394407PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen, S, Carpenter, G 1975Human epidermal growth factor: isolation and chemical and biological propertiesProc Natl Acad Sci USA7213171321PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen, S, Carpenter, G, King, L,Jr 1980Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activityJ Biol Chem25548344842PubMedGoogle Scholar
  11. 11.
    Burgess, AW, Cho, HS, Eigenbrot, C,  et al. 2003An open-and-shut case? Recent insights into the activation of EGF/ErbB receptorsMol Cell12541552PubMedCrossRefGoogle Scholar
  12. 12.
    Thomas, SM, Coppelli, FM, Wells, A,  et al. 2003Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinomaCancer Res6356295635PubMedGoogle Scholar
  13. 13.
    Kalyankrishna, S, Grandis, JR 2006Epidermal growth factor receptor biology in head and neck cancerJ Clin Oncol2426662672PubMedCrossRefGoogle Scholar
  14. 14.
    Schulze, WX, Deng, L, Mann, M 2005Phosphotyrosine interactome of the ErbB-receptor kinase familyMol Syst Biol120050008PubMedCrossRefGoogle Scholar
  15. 15.
    Goldman, R, Levy, RB, Peles, E,  et al. 1990Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulationBiochemistry291102411028PubMedCrossRefGoogle Scholar
  16. 16.
    Pinkas-Kramarski, R, Soussan, L, Waterman, H,  et al. 1996Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactionsEMBO J1524522467PubMedGoogle Scholar
  17. 17.
    Yarden, Y 2001The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunitiesEur J Cancer37S3S8PubMedCrossRefGoogle Scholar
  18. 18.
    Gilmore, AP, Valentijn, AJ, Wang, P,  et al. 2002Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptorJ Biol Chem2772764327650PubMedCrossRefGoogle Scholar
  19. 19.
    Kim, YN, Dam, P, Bertics, PJ 2002Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activationExp Cell Res280134147PubMedCrossRefGoogle Scholar
  20. 20.
    Andreev, J, Galisteo, ML, Kranenburg, O,  et al. 2001Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascadeJ Biol Chem2762013020135PubMedCrossRefGoogle Scholar
  21. 21.
    Darnell, JE,Jr, Kerr, IM, Stark, GR 1994Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteinsScience26414151421PubMedCrossRefGoogle Scholar
  22. 22.
    Kijima, T, Niwa, H, Steinman, RA,  et al. 2002STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivoCell Growth Differ13355362PubMedGoogle Scholar
  23. 23.
    Xi, S, Zhang, Q, Gooding, WE,  et al. 2003Constitutive activation of Stat5b contributes to carcinogenesis in vivoCancer Res6367636771PubMedGoogle Scholar
  24. 24.
    Harari, PM, Huang, S 2006Radiation combined with EGFR signal inhibitors: head and neck cancer focusSemin Radiat Oncol163844PubMedCrossRefGoogle Scholar
  25. 25.
    Hynes, NE, Lane, HA 2005ERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer5341354PubMedCrossRefGoogle Scholar
  26. 26.
    Lin, SY, Makino, K, Xia, W,  et al. 2001Nuclear localization of EGF receptor and its potential new role as a transcription factorNat Cell Biol3802808PubMedCrossRefGoogle Scholar
  27. 27.
    Dittmann, K, Mayer, C, Fehrenbacher, B,  et al. 2005Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinaseJ Biol Chem2803118231189PubMedCrossRefGoogle Scholar
  28. 28.
    Lo, HW, Hsu, SC, Ali-Seyed, M,  et al. 2005Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathwayCancer Cell7575589PubMedCrossRefGoogle Scholar
  29. 29.
    Lo, HW, Hung, MC 2006Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survivalBr J Cancer94184188PubMedCrossRefGoogle Scholar
  30. 30.
    Hanada, N, Lo, HW, Day, CP,  et al. 2006Co-regulation of B-Myb expression by E2F1 and EGF receptorMol Carcinog451017PubMedCrossRefGoogle Scholar
  31. 31.
    Khanna, KK, Jackson, SP 2001DNA double-strand breaks: signaling, repair and the cancer connectionNat Genet27247254PubMedCrossRefGoogle Scholar
  32. 32.
    Warren, CM, Landgraf, R 2006Signaling through ERBB receptors: multiple layers of diversity and controlCell Signal18923933PubMedCrossRefGoogle Scholar
  33. 33.
    Levkowitz, G, Waterman, H, Ettenberg, SA,  et al. 1999Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1Mol Cell410291040PubMedCrossRefGoogle Scholar
  34. 34.
    Wiley, HS 2003Trafficking of the ErbB receptors and its influence on signalingExp Cell Res2847888PubMedCrossRefGoogle Scholar
  35. 35.
    Boerner, JL, Demory, ML, Silva, C,  et al. 2004Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit IIMol Cell Biol2470597071PubMedCrossRefGoogle Scholar
  36. 36.
    Grandis, JR, Tweardy, DJ 1993Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancerCancer Res5335793584PubMedGoogle Scholar
  37. 37.
    Rubin Grandis, J, Melhem, MF, Barnes, EL,  et al. 1996Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neckCancer7812841292PubMedCrossRefGoogle Scholar
  38. 38.
    Shin, DM, Ro, JY, Hong, WK,  et al. 1994Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesisCancer Res5431533159PubMedGoogle Scholar
  39. 39.
    Rubin Grandis, J, Zeng, Q, Tweardy, DJ 1996Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell linesNat Med2237240PubMedCrossRefGoogle Scholar
  40. 40.
    Schmidt-Ullrich, RK, Mikkelsen, RB, Dent, P,  et al. 1997Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylationOncogene1511911197PubMedCrossRefGoogle Scholar
  41. 41.
    Sok, JC, Coppelli, FM, Thomas, SM,  et al. 2006Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targetingClin Cancer Res1250645073PubMedCrossRefGoogle Scholar
  42. 42.
    Wikstrand, CJ, McLendon, RE, Friedman, AH,  et al. 1997Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIIICancer Res5741304140PubMedGoogle Scholar
  43. 43.
    Lynch, TJ, Bell, DW, Sordella, R,  et al. 2004Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med35021292139PubMedCrossRefGoogle Scholar
  44. 44.
    Etienne-Grimaldi, MC, Pereira, S, Magne, N,  et al. 2005Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patientsAnn Oncol16934941PubMedCrossRefGoogle Scholar
  45. 45.
    Cappuzzo, F, Varella-Garcia, M, Shigematsu, H,  et al. 2005Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patientsJ Clin Oncol2350075018PubMedCrossRefGoogle Scholar
  46. 46.
    Psyrri, A, Yu, Z, Weinberger, PM,  et al. 2005Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysisClin Cancer Res1158565862PubMedCrossRefGoogle Scholar
  47. 47.
    Milas, L, Akimoto, T, Hunter, NR,  et al. 2002Relationship between cyclin D1 expression and poor radioresponse of murine carcinomasInt J Radiat Oncol Biol Phys52514521PubMedCrossRefGoogle Scholar
  48. 48.
    Withers, HR, Taylor, JM, Maciejewski, B 1988The hazard of accelerated tumor clonogen repopulation during radiotherapyActa Oncol27131146PubMedGoogle Scholar
  49. 49.
    Schmidt-Ullrich, RK, Valerie, K, Chan, W,  et al. 1992Expression of oestrogen receptor and transforming growth factor-alpha in MCF-7 cells after exposure to fractionated irradiationInt J Radiat Biol61405415PubMedGoogle Scholar
  50. 50.
    Kavanagh, BD, Lin, PS, Chen, P,  et al. 1995Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factorClin Cancer Res115571562PubMedGoogle Scholar
  51. 51.
    Schmidt-Ullrich, RK, Contessa, JN, Lammering, G,  et al. 2003ERBB receptor tyrosine kinases and cellular radiation responsesOncogene2258555865PubMedCrossRefGoogle Scholar
  52. 52.
    Akimoto, T, Hunter, NR, Buchmiller, L,  et al. 1999Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomasClin Cancer Res528842890PubMedGoogle Scholar
  53. 53.
    Ang, KK, Berkey, BA, Tu, X,  et al. 2002Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinomaCancer Res6273507356PubMedGoogle Scholar
  54. 54.
    Liang, K, Ang, KK, Milas, L,  et al. 2003The epidermal growth factor receptor mediates radioresistanceInt J Radiat Oncol Biol Phys57246254PubMedCrossRefGoogle Scholar
  55. 55.
    Mendelsohn, J, Masui, H, Goldenberg, A 1987Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathwayTrans Assoc Am Physicians100173178PubMedGoogle Scholar
  56. 56.
    Sato, JD, Kawamoto, T, Le, AD,  et al. 1983Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptorsMol Biol Med1511529PubMedGoogle Scholar
  57. 57.
    Balaban, N, Moni, J, Shannon, M,  et al. 1996The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiationBiochim Biophys Acta1314147156PubMedCrossRefGoogle Scholar
  58. 58.
    Saleh, MN, Raisch, KP, Stackhouse, MA,  et al. 1999Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiationCancer Biother Radiopharm14451463PubMedGoogle Scholar
  59. 59.
    Huang, SM, Bock, JM, Harari, PM 1999Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neckCancer Res5919351940PubMedGoogle Scholar
  60. 60.
    Huang, SM, Harari, PM 1999Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical resultsInvest New Drugs17259269PubMedCrossRefGoogle Scholar
  61. 61.
    Milas, L, Mason, K, Hunter, N,  et al. 2000In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibodyClin Cancer Res6701708PubMedGoogle Scholar
  62. 62.
    Nasu, S, Ang, KK, Fan, Z,  et al. 2001C225 antiepidermal growth factor receptor antibody enhances tumor radiocurabilityInt J Radiat Oncol Biol Phys51474477PubMedCrossRefGoogle Scholar
  63. 63.
    Bianco, C, Tortora, G, Bianco, R,  et al. 2002Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)Clin Cancer Res832503258PubMedGoogle Scholar
  64. 64.
    She, Y, Lee, F, Chen, J,  et al. 2003The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic indexClin Cancer Res937733778PubMedGoogle Scholar
  65. 65.
    Chinnaiyan, P, Huang, S, Vallabhaneni, G,  et al. 2005Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)Cancer Res6533283335PubMedGoogle Scholar
  66. 66.
    Solomon, B, Hagekyriakou, J, Trivett, MK,  et al. 2003EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinomaInt J Radiat Oncol Biol Phys55713723PubMedCrossRefGoogle Scholar
  67. 67.
    Huang, SM, Harari, PM 2000Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesisClin Cancer Res621662174PubMedGoogle Scholar
  68. 68.
    Huang, SM, Li, J, Harari, PM 2002Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockadeMol Cancer Ther1507514PubMedGoogle Scholar
  69. 69.
    Baumann, M, Krause, M 2004Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical resultsRadiother Oncol72257266PubMedCrossRefGoogle Scholar
  70. 70.
    Bonner, JA, Raisch, KP, Trummell, HQ,  et al. 2000Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancersJ Clin Oncol1847S53SPubMedGoogle Scholar
  71. 71.
    Rowinsky, EK 2004The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitorsAnnu Rev Med55433457PubMedCrossRefGoogle Scholar
  72. 72.
    Li, S, Schmitz, KR, Jeffrey, PD,  et al. 2005Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell7301311PubMedCrossRefGoogle Scholar
  73. 73.
    Dent, P, Reardon, DB, Park, JS,  et al. 1999Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell deathMol Biol Cell1024932506PubMedGoogle Scholar
  74. 74.
    Bonner, JA, Harari, PM, Giralt, J,  et al. 2006Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med354567578PubMedCrossRefGoogle Scholar
  75. 75.
    Harari, PM, Hartig, GK 2003Impact of the EGFR inhibitor C225 on wound healing in advanced head and neck cancer patients undergoing neck dissectionJ Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition)22220Google Scholar
  76. 76.
    Bonner, JA, Giralt, J 2005Improved preservation of larynx with the addition of cetuximab to radiation of cetuximab for cancers of the larynx and hypopharynxJ Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition)235533Google Scholar
  77. 77.
    Pfister, DG, Su, YB, Kraus, DH,  et al. 2006Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigmJ Clin Oncol2410721078PubMedCrossRefGoogle Scholar
  78. 78.
    De La Garza JG, Granados M, Aguilar JL, et al. (2006) Phase II clinical trial preliminary report: Cetuximab, gemcitabine and simultaneous radiotherapy for locally advanced head and neck cancer: Preliminary report J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24:15 502Google Scholar
  79. 79.
    Chua, DT, Nicholls, JM, Sham, JS,  et al. 2004Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapyInt J Radiat Oncol Biol Phys591120PubMedCrossRefGoogle Scholar
  80. 80.
    Bentzen, SM, Atasoy, BM, Daley, FM,  et al. 2005Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trialJ Clin Oncol2355605567PubMedCrossRefGoogle Scholar
  81. 81.
    Eriksen, JG, Steiniche, T, Askaa, J,  et al. 2004The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neckInt J Radiat Oncol Biol Phys58561566PubMedCrossRefGoogle Scholar
  82. 82.
    Psyrri, A, Fountzilas, G 2006Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck regionMed Oncol23115PubMedCrossRefGoogle Scholar
  83. 83.
    Burtness, B, Goldwasser, MA, Flood, W,  et al. 2005Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyJ Clin Oncol2386468654PubMedCrossRefGoogle Scholar
  84. 84.
    Soulieres, D, Senzer, NN, Vokes, EE,  et al. 2004Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol227785PubMedCrossRefGoogle Scholar
  85. 85.
    Saltz, L 2005Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?Clin Colorectal Cancer5S98S100PubMedGoogle Scholar
  86. 86.
    Chung, KY, Shia, J, Kemeny, NE,  et al. 2005Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryJ Clin Oncol2318031810PubMedCrossRefGoogle Scholar
  87. 87.
    Dziadziuszko, R, Hirsch, FR, Varella-Garcia, M,  et al. 2006Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization – why, when, and how?Clin Cancer Res124409s4415sPubMedCrossRefGoogle Scholar
  88. 88.
    Loeffler-Ragg, J, Witsch-Baumgartner, M, Tzankov, A,  et al. 2006Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinomaEur J Cancer42109111PubMedCrossRefGoogle Scholar
  89. 89.
    Lee, JS, Ro, JS, Eisbruch, A,  et al. 1988Multiple restriction fragment length polymorphisms of the human epidermal growth factor receptor geneCancer Res4840454048PubMedGoogle Scholar
  90. 90.
    Cohen, EE, Rosen, F, Stadler, WM,  et al. 2003Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neckJ Clin Oncol2119801987PubMedCrossRefGoogle Scholar
  91. 91.
    Gibson, TB, Ranganathan, A, Grothey, A 2006Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancerClin Colorectal Cancer62931PubMedCrossRefGoogle Scholar
  92. 92.
    Baselga, J, Trigo, JM, Bourhis, J,  et al. 2005Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neckJ Clin Oncol2355685577PubMedCrossRefGoogle Scholar
  93. 93.
    Choong, NW, Cohen, EE 2006Epidermal growth factor receptor directed therapy in head and neck cancerCrit Rev Oncol Hematol572543PubMedGoogle Scholar
  94. 94.
    Milas, L, Fang, F, Mason, KA,  et al. 2007Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiationInt J Radiat Oncol Biol Phys1568572Google Scholar
  95. 95.
    Crombet, T, Osorio, M, Cruz, T,  et al. 2004Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol2216461654PubMedCrossRefGoogle Scholar
  96. 96.
    Lynch, DH, Yang, XD 2002Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatmentSemin Oncol294750PubMedCrossRefGoogle Scholar
  97. 97.
    Cohen, EE 2006Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckJ Clin Oncol2426592665PubMedCrossRefGoogle Scholar
  98. 98.
    Herchenhorn, D, Dias, FL, Ferreira, CG,  et al. 2006Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition)245575Google Scholar
  99. 99.
    Savvides, P, Agarwala, SS, Greskovich, J,  et al. 2006Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN)J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition)245545Google Scholar
  100. 100.
    Allen, CT, Donovan, EA, Chen, Z,  et al. 2006Clinical, signaling pathway, and cellular effects of epidermal growth factor receptor (EGFR) inhibition with gefitinib in combination with paclitaxel and radiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition)2415540Google Scholar
  101. 101.
    Doss, HH, Greco, FA, Meluch, AA,  et al. 2006Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition)245543Google Scholar
  102. 102.
    Lawrence, TS, Nyati, MK 2002Small-molecule tyrosine kinase inhibitors as radiosensitizersSemin Radiat Oncol123336PubMedCrossRefGoogle Scholar
  103. 103.
    Nyati, MK, Maheshwari, D, Hanasoge, S,  et al. 2004Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivoClin Cancer Res10691700PubMedCrossRefGoogle Scholar
  104. 104.
    Dewji, MR 2004Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?J Chemother164448PubMedGoogle Scholar
  105. 105.
    Calvo, E, Tolcher, AW, Hammond, LA,  et al. 2004Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyClin Cancer Res1071127120PubMedCrossRefGoogle Scholar
  106. 106.
    Nemunaitis, J, Eiseman, I, Cunningham, C,  et al. 2005Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerClin Cancer Res1138463853PubMedCrossRefGoogle Scholar
  107. 107.
    Campos, S, Hamid, O, Seiden, MV,  et al. 2005Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancerJ Clin Oncol2355975604PubMedCrossRefGoogle Scholar
  108. 108.
    Garland, LL, Hidalgo, M, Mendelson, DS,  et al. 2006A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumorsClin Cancer Res1242744282PubMedCrossRefGoogle Scholar
  109. 109.
    Wood, ER, Truesdale, AT, McDonald, OB,  et al. 2004A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cellsCancer Res6466526659PubMedCrossRefGoogle Scholar
  110. 110.
    Harrington K, Bourhis J, Nutting CM, et al. (2006) A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)Google Scholar
  111. 111.
    Matar, P, Rojo, F, Cassia, R,  et al. 2004Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targetingClin Cancer Res1064876501PubMedCrossRefGoogle Scholar
  112. 112.
    Huang, S, Armstrong, EA, Benavente, S,  et al. 2004Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitorCancer Res6453555362PubMedCrossRefGoogle Scholar
  113. 113.
    Baselga, J, Schöffski, P, Rojo, F,  et al. 2006A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC)J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition)243006Google Scholar
  114. 114.
    Lee, D 2005Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancerClin Lung Cancer78991PubMedGoogle Scholar
  115. 115.
    Pedersen, MW, Meltorn, M, Damstrup, L,  et al. 2001The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapyAnn Oncol12745760PubMedCrossRefGoogle Scholar
  116. 116.
    Lammering, G, Hewit, TH, Valerie, K,  et al. 2003EGFRvIII-mediated radioresistance through a strong cytoprotective responseOncogene2255455553PubMedCrossRefGoogle Scholar
  117. 117.
    Zhan, M, Han, ZC 2004Phosphatidylinositide 3-kinase/AKT in radiation responsesHistol Histopathol19915923PubMedGoogle Scholar
  118. 118.
    Pedrero, JM, Carracedo, DG, Pinto, CM,  et al. 2005Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinomaInt J Cancer114242248PubMedCrossRefGoogle Scholar
  119. 119.
    Okami, K, Wu, L, Riggins, G,  et al. 1998Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumorsCancer Res58509511PubMedGoogle Scholar
  120. 120.
    Motoyama, AB, Hynes, NE, Lane, HA 2002The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptidesCancer Res6231513158PubMedGoogle Scholar
  121. 121.
    Hurbin, A, Dubrez, L, Coll, JL,  et al. 2002Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell linesJ Biol Chem2774912749133PubMedCrossRefGoogle Scholar
  122. 122.
    Chakravarti, A, Loeffler, JS, Dyson, NJ 2002Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signalingCancer Res62200207PubMedGoogle Scholar
  123. 123.
    Daub, H, Weiss, FU, Wallasch, C,  et al. 1996Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptorsNature379557560PubMedCrossRefGoogle Scholar
  124. 124.
    Thomas, S, Wentzel, AQZ 2005Prostaglandin E2 and bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanismsProc Am Assoc Cancer Res46169Google Scholar
  125. 125.
    Hart, S, Fischer, OM, Prenzel, N,  et al. 2005GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathwaysBiol Chem386845855PubMedCrossRefGoogle Scholar
  126. 126.
    Krysan, K, Reckamp, KL, Dalwadi, H,  et al. 2005Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent mannerCancer Res6562756281PubMedCrossRefGoogle Scholar
  127. 127.
    Bowers, G, Reardon, D, Hewitt, T,  et al. 2001The relative role of ErbB1–4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cellsOncogene2013881397PubMedCrossRefGoogle Scholar
  128. 128.
    Wild-Bode, C, Weller, M, Rimner, A,  et al. 2001Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastomaCancer Res6127442750PubMedGoogle Scholar
  129. 129.
    Eisma, RJ, Spiro, JD, Kreutzer, DL 1997Vascular endothelial growth factor expression in head and neck squamous cell carcinomaAm J Surg174513517PubMedCrossRefGoogle Scholar
  130. 130.
    Viloria-Petit, A, Crombet, T, Jothy, S,  et al. 2001Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesisCancer Res6150905101PubMedGoogle Scholar
  131. 131.
    Lu, Y, Zi, X, Zhao, Y,  et al. 2001Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst9318521857PubMedCrossRefGoogle Scholar
  132. 132.
    Tonra, JR, Deevi, DS, Corcoran, E,  et al. 2006Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapyClin Cancer Res1221972207PubMedCrossRefGoogle Scholar
  133. 133.
    Traxler, P, Allegrini, PR, Brandt, R,  et al. 2004AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activityCancer Res6449314941PubMedCrossRefGoogle Scholar
  134. 134.
    Hennequin, LF, Thomas, AP, Johnstone, C,  et al. 1999Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitorsJ Med Chem4253695389PubMedCrossRefGoogle Scholar
  135. 135.
    Yigitbasi, OG, Younes, MN, Doan, D,  et al. 2004Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockadeCancer Res6479777984PubMedCrossRefGoogle Scholar
  136. 136.
    Wedge, SR, Ogilvie, DJ, Dukes, M,  et al. 2002ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res6246454655PubMedGoogle Scholar
  137. 137.
    Ciardiello, F, Caputo, R, Damiano, V,  et al. 2003Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinaseClin Cancer Res915461556PubMedGoogle Scholar
  138. 138.
    Williams, KJ, Telfer, BA, Brave, S,  et al. 2004ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activityClin Cancer Res1085878593PubMedCrossRefGoogle Scholar
  139. 139.
    Morelli, MP, Cascone, T, Troiani, T,  et al. 2006Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinasesJ Cell Physiol208344353PubMedCrossRefGoogle Scholar
  140. 140.
    Brazelle, WD, Shi, W, Siemann, DW 2006VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapyInt J Radiat Oncol Biol Phys65836841PubMedGoogle Scholar
  141. 141.
    Kwak, EL, Sordella, R, Bell, DW,  et al. 2005Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci USA10276657670PubMedCrossRefGoogle Scholar
  142. 142.
    Morelli, MP, Cascone, T, Troiani, T,  et al. 2006Antitumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinasesJ Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition)24131Google Scholar
  143. 143.
    Heymach, JV 2005ZD6474–clinical experience to dateBr J Cancer92S1420PubMedCrossRefGoogle Scholar
  144. 144.
    Holden, SN, Eckhardt, SG, Basser, R,  et al. 2005Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnn Oncol1613911397PubMedCrossRefGoogle Scholar
  145. 145.
    Williamson, SK, Moon, J, Huang, CH,  et al. 2006A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trialJ Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition)245550Google Scholar

Copyright information

© The Japan Society of Clinical Oncology 2007

Authors and Affiliations

  • Juliette Thariat
    • 1
  • Gokcen Yildirim
    • 2
  • Kathryn A. Mason
    • 1
  • Adam S. Garden
    • 2
  • Luka Milas
    • 1
  • K. Kian Ang
    • 2
    Email author
  1. 1.Department of Experimental Radiation OncologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Radiation OncologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations